Evolving strategies for addressing CAR T-cell toxicities.

Area of Science:

• Immunotherapy
• Oncology
• Cellular Therapy

Background:

• Chimeric antigen receptor (CAR) T-cell therapy has evolved into a significant treatment modality for hematologic malignancies.
• Six CAR T-cell products are currently FDA-approved, demonstrating clinical efficacy.
• CAR T-cell therapy is associated with significant toxicities that necessitate careful management.

Purpose of the Study:

• To review the most common toxicities associated with CAR T-cell therapy.
• To highlight risk factors, prognostication, and critical care management implications.
• To discuss patient experience optimization and ongoing efforts in toxicity mitigation.

Main Methods:

• Literature review of common CAR T-cell toxicities.
• Analysis of risk factors and prognostication strategies.
• Discussion of clinical management and patient care.

Main Results:

• Common toxicities of CAR T-cell therapy are identified.
• Key risk factors and prognostic indicators are presented.
• Strategies for critical care and patient experience are outlined.

Conclusions:

• Understanding CAR T-cell toxicities is crucial for effective clinical application.
• Management of toxicities requires timely and thoughtful interventions.
• Ongoing research aims to mitigate adverse events and improve patient outcomes.